ja3c02679_si_001.pdf (10.52 MB)
Antigen/Adjuvant-Displaying Enveloped Viral Replica as a Self-Adjuvanting Anti-Breast-Cancer Vaccine Candidate
journal contributionposted on 2023-06-20, 15:04 authored by Keita Ito, Hiroto Furukawa, Hiroshi Inaba, Shino Ohshima, Yoshie Kametani, Masatoshi Maeki, Manabu Tokeshi, Xuhao Huang, Kazuya Kabayama, Yoshiyuki Manabe, Koichi Fukase, Kazunori Matsuura
We report a promising cancer vaccine candidate comprising antigen/adjuvant-displaying enveloped viral replica as a novel vaccine platform. The artificial viral capsid, which consists of a self-assembled β-annulus peptide conjugated with an HER2-derived antigenic CH401 peptide, was enveloped within a lipid bilayer containing the lipidic adjuvant α-GalCer. The use of an artificial viral capsid as a scaffold enabled precise control of its size to ∼100 nm, which is generally considered to be optimal for delivery to lymph nodes. The encapsulation of the anionically charged capsid by a cationic lipid bilayer dramatically improved its stability and converted its surface charge to cationic, enhancing its uptake by dendritic cells. The developed CH401/α-GalCer-displaying enveloped viral replica exhibited remarkable antibody-production activity. This study represents a pioneering example of precise vaccine design through bottom-up construction and opens new avenues for the development of effective vaccines.
∼ 100 nmprecise vaccine designopens new avenuesnovel vaccine platformlipid bilayer containingcancer vaccine candidateartificial viral capsidannulus peptide conjugatedanionically charged capsidlipidic adjuvant αsurface chargestudy representsproduction activitypioneering examplelymph nodesgenerally consideredenveloped withineffective vaccinesdeveloped ch401dendritic cellsassembled βadjuvanting anti